Osteoarthritis: an update with relevance for clinical practice

被引:2294
作者
Bijlsma, Johannes W. J. [1 ]
Berenbaum, Francis [2 ]
Lafeber, Foris P. J. G. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands
[2] Univ Paris 06, Hosp St Antoine, Dept Rheumatol, Paris, France
关键词
JOINT-SPACE WIDTH; INDIVIDUAL RADIOGRAPHIC FEATURES; EVIDENCE BASED RECOMMENDATIONS; HUMAN ARTICULAR-CARTILAGE; EULAR-STANDING-COMMITTEE; GLYCATION END-PRODUCTS; KNEE OSTEOARTHRITIS; SUBCHONDRAL BONE; HAND OSTEOARTHRITIS; MATRIX METALLOPROTEINASES;
D O I
10.1016/S0140-6736(11)60243-2
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Osteoarthritis is thought to be the most prevalent chronic joint disease. The incidence of osteoarthritis is rising because of the ageing population and the epidemic of obesity. Pain and loss of function are the main clinical features that lead to treatment, including non-pharmacological, pharmacological, and surgical approaches. Clinicians recognise that the diagnosis of osteoarthritis is established late in the disease process, maybe too late to expect much help from disease-modifying drugs. Despite efforts over the past decades to develop markers of disease, still-imaging procedures and biochemical marker analyses need to be improved and possibly extended with more specific and sensitive methods to reliably describe disease processes, to diagnose the disease at an early stage, to classify patients according to their prognosis, and to follow the course of disease and treatment effectiveness. In the coming years, a better definition of osteoarthritis is expected by delineating different phenotypes of the disease. Treatment targeted more specifically at these phenotypes might lead to improved outcomes.
引用
收藏
页码:2115 / 2126
页数:12
相关论文
共 141 条
[1]
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis [J].
Abadie, E ;
Ethgen, D ;
Avouac, B ;
Bouvenot, G ;
Branco, J ;
Bruyere, O ;
Calvo, G ;
Devogelaer, JP ;
Dreiser, RL ;
Herrero-Beaumont, G ;
Kahan, A ;
Kreutz, G ;
Laslop, A ;
Lemme, EM ;
Nuki, G ;
Van de Putte, L ;
Vanhaelst, L ;
Reginster, JY .
OSTEOARTHRITIS AND CARTILAGE, 2004, 12 (04) :263-268
[2]
Atlas of individual radiographic features in osteoarthritis, revised [J].
Altman, R. D. ;
Gold, G. E. .
OSTEOARTHRITIS AND CARTILAGE, 2007, 15 :A1-A56
[3]
ALTMAN RD, 1991, J RHEUMATOL, V18, P10
[4]
Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage - Influence of nitric oxide [J].
Amin, AR ;
Attur, M ;
Patel, RN ;
Thakker, GD ;
Marshall, PJ ;
Rediske, J ;
Stuchin, SA ;
Patel, IR ;
Abramson, SB .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (06) :1231-1237
[5]
Anandacoomarasamy AL, 2010, EULAR 2010 ROM IT JU
[6]
Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis [J].
Andersson, M. L. E. ;
Petersson, I. F. ;
Karlsson, K. E. ;
Jonsson, E. N. ;
Mansson, B. ;
Heinegard, D. ;
Saxne, T. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (11) :1490-1494
[7]
Simultaneous computed tomography of articular cartilage and subchondral bone [J].
Aula, A. S. ;
Jurvelin, J. S. ;
Toyras, J. .
OSTEOARTHRITIS AND CARTILAGE, 2009, 17 (12) :1583-1588
[8]
Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints [J].
Aurich, M ;
Squires, GR ;
Reiner, A ;
Mollenhauer, JA ;
Kuettner, KE ;
Poole, AR ;
Cole, AA .
ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :112-119
[9]
Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials [J].
Avouac, J. ;
Gossec, L. ;
Dougados, M. .
OSTEOARTHRITIS AND CARTILAGE, 2007, 15 (08) :957-965
[10]
Bailey AJ, 2004, BIORHEOLOGY, V41, P349